Advanced search
Publication Cover
Immunotherapy Volume 2, 2010 - Issue 3
Submit an article Journal homepage
168
Views
0
CrossRef citations to date
0
Altmetric
Review

Kinoids: A Family of Immunogens for Active Anticytokine Immunotherapy Applied to Autoimmune Diseases and Cancer

Bernard Bizzini1 Honorary Head of Department of the Pasteur Institute, Paris, France
,
Béatrice Drouet2 Néovacs, SA 3–5, Impasse, Reille, 75014Paris, France
,
Daniel Zagury2 Néovacs, SA 3–5, Impasse, Reille, 75014Paris, FranceCorrespondence[email protected]
,
Marc Abitbol3 CERTO, Paris, France
,
Arsène Burny4 ULB IBMM, Gosselies, Belgium
&
Marie-Christophe Boissier5 CHU Avicenne (APHP), Rheumatology Department, Bobigny, France;6 University of Paris 13, Li2P, EA 4222, Paris, France
Pages 347-365 | Published online: 10 May 2010

Bibliography

  • Thomson A : The Cytokine Handbook. Academic Press, CA, USA (1998).
  • Germann T , GatelyMK, SchoenhautDSet al.: Interleukin-12/T cell stimulating factor, a cytokine with multiple effects on T helper type 1 (Th1) but not on Th2 cells.Eur. J. Immunol.23(8) , 1762–1770 (1993).
  • Langowski JL , ZhangX, WuLet al.: IL-23 promotes tumour incidence and growth.Nature442(7101) , 461–465 (2006).
  • Lieberman LA , CardilloF, OwyangAMet al.: IL-23 provides a limited mechanism of resistance to acute toxoplasmosis in the absence of IL-12.J. Immunol.173(3) , 1887–1893 (2004).
  • McKenzie BS , KasteleinRA, CuaDJ: Understanding the IL-23–IL-17 immune pathway.Trends Immunol.27(1) , 17–23 (2006).
  • Happel KI , ZhengM, YoungEet al.: Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection.J. Immunol.170(9) , 4432–4436 (2003).
  • Carswell EA , OldLJ, KasselRLet al.: An endotoxin-induced serum factor that causes necrosis of tumors.Proc. Natl Acad. Sci. USA72(9) , 3666–3670 (1975).
  • Blanco P , PaluckaAK, PascualV, BanchereauJ: Dendritic cells and cytokines in human inflammatory and autoimmune diseases.Cytokine Growth Factor Rev.19(1) , 41–52 (2008).
  • Zagury D , BurnyA, GalloRC: Toward a new generation of vaccines: the anti-cytokine therapeutic vaccines.Proc. Natl Acad. Sci. USA98(14) , 8024–8029 (2001).
  • Stewart TJ , SmythMJ: Chemokine–chemokine receptors in cancer immunotherapy.Immunotherapy1(1) , 109–127 (2009).
  • Croft M : The role of TNF superfamily members in T-cell function and diseases.Nat. Rev. Immunol.9(4) , 271–285 (2009).
  • Sarkar S , CooneyLA, WhitePet al.: Regulation of pathogenic IL-17 responses in collagen-induced arthritis: roles of endogenous interferon-γ and IL-4.Arthritis Res. Ther.11(5) , R158 (2009).
  • Wilson NJ , BonifaceK, ChanJRet al.: Development, cytokine profile and function of human interleukin 17-producing helper T cells.Nat. Immunol.8(9) , 950–957 (2007).
  • Acosta-Rodriguez EV , NapolitaniG, LanzavecchiaA, SallustoF: Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper cells.Nat. Immunol.8(9) , 942–949 (2007).
  • Annunziato F , CosmiL, LiottaF, MaggiE, RomagnaniS: Type 17 T helper cells-origins, features and possible roles in rheumatic disease.Nat. Rev. Rheumatol.5(6) , 325–331 (2009).
  • Boissier MC , AssierE, BitonJet al.: Regulatory T cells (Treg) in rheumatoid arthritis.Joint Bone Spine76(1) , 10–14 (2009).
  • Delavallee L , AssierE, SemeranoL, BessisN, BoissierMC: Emerging applications of anticytokine vaccines.Expert Rev. Vaccines7(10) , 1507–1517 (2008).
  • Genovese MC , McKayJD, NasonovELet al.: Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.Arthritis Rheum.58(10) , 2968–2980 (2008).
  • Genovese M , Van den Bosch F, Roberson S et al.: LY2439821, a humanized anti-IL-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis. Arthritis Rheum.62(4) , 929–939 (2010).
  • Keffer J , ProbertL, CazlarisHet al.: Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis.EMBO J.10(13) , 4025–4031 (1991).
  • Brombacher F , KasteleinRA, AlberG: Novel IL-12 family members shed light on the orchestration of Th1 responses.Trends Immunol.24(4) , 207–212 (2003).
  • O‘Neill JL , KalbRE: Ustekinumab in the therapy of chronic plaque psoriasis.Biologics3 , 159–168 (2009).
  • Andoh A , YagiY, ShioyaMet al.: Mucosal cytokine network in inflammatory bowel disease.World J. Gastroenterol.14(33) , 5154–5161 (2008).
  • Choo-Kang BS , HutchisonS, NickdelMBet al.: TNF-blocking therapies: an alternative mode of action?Trends Immunol.26(10) , 518–222 (2005).)
  • Lipsky PE , van der Heijde DM, St Clair EW et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med.343(22) , 1594–1602 (2000).
  • Weinblatt ME , KeystoneEC, FurstDEet al.: Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study.Ann. Rheum. Dis.65(6) , 753–759 (2006).
  • Weinblatt ME , KremerJM, BankhurstADet al.: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.N. Engl. J. Med.340(4) , 253–259 (1999).
  • Lang L : FDA approves Cimzia to treat Crohn‘s disease.Gastroenterology134(7) , 1819 (2008).
  • Pappas DA , BathonJM, HanicqD, YasothanU, KirkpatrickP: Golimumab.Nat. Rev. Drug. Discov.8(9) , 695–696 (2009).
  • Rahman A , IsenbergDA: Systemic lupus erythematosus.N. Engl. J. Med.358(9) , 929–939 (2008).
  • Ronnblom L , ElorantaML, AlmGV: The type I interferon system in systemic lupus erythematosus.Arthritis Rheum.54(2) , 408–420 (2006).
  • Stewart TA : Neutralizing interferon α as a therapeutic approach to autoimmune diseases.Cytokine Growth Factor Rev.14(2) , 139–154 (2003).
  • Pascual V , FarkasL, BanchereauJ: Systemic lupus erythematosus: all roads lead to type I interferons.Curr. Opin. Immunol.18(6) , 676–682 (2006).
  • Batteux F , PalmerP, DaeronM, WeillB, LebonP: FCγRII (CD32)-dependent induction of interferon-α by serum from patients with lupus erythematosus.Eur. Cytokine Netw.10(4) , 509–514 (1999).
  • Hochberg MC : Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.Arthritis Rheum.40(9) , 1725 (1997).
  • Baechler EC , BatliwallaFM, KarypisGet al.: Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus.Proc. Natl Acad. Sci. USA100(5) , 2610–2615 (2003).
  • Bauer JW , PetriM, BatliwallaFMet al.: Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study.Arthritis Rheum.60(10) , 3098–3107 (2009).
  • Landolt-Marticorena C , BonventiG, LubovichAet al.: Lack of association between the interferon-α signature and longitudinal changes in disease activity in systemic lupus erythematosus.Ann. Rheum. Dis.68(9) , 1440–1446 (2009).
  • Means TK , LatzE, HayashiFet al.: Human lupus autoantibody–DNA complexes activate DCs through cooperation of CD32 and TLR9.J. Clin. Invest.115(2) , 407–417 (2005).
  • Sledz CA , HolkoM, de Veer MJ, Silverman RH, Williams BR: Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol.5(9) , 834–839 (2003).
  • Lovgren T , ElorantaML, BaveU, AlmGV, RonnblomL: Induction of interferon-α production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG.Arthritis Rheum.50(6) , 1861–1872 (2004).
  • Zhuang H , NarainS, SobelEet al.: Association of anti-nucleoprotein autoantibodies with upregulation of Type I interferon-inducible gene transcripts and dendritic cell maturation in systemic lupus erythematosus.Clin. Immunol.117(3) , 238–250 (2005).
  • Hua J , KirouK, LeeC, CrowMK: Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies.Arthritis Rheum.54(6) , 1906–1916 (2006).
  • Capobianchi MR , AmeglioF, Cordiali Fei P et al.: Coordinate induction of interferon α and γ by recombinant HIV-1 glycoprotein 120. AIDS Res. Hum. Retroviruses9(10) , 957–962 (1993).
  • Zagury D , BernardJ, HalbreichAet al.: One-year follow-up of vaccine therapy in HIV-infected immune-deficient individuals: a new strategy.J. Acquir. Immune Defic. Syndr.5(7) , 676–681 (1992).
  • Marcuzzi A , WeinbergerJ, WeinbergerOK: Transcellular activation of the human immunodeficiency virus type 1 long terminal repeat in cocultured lymphocytes.J. Virol.66(7) , 4228–4232 (1992).
  • Zauli G , DavisBR, ReMCet al.: tat protein stimulates production of transforming growth factor-β 1 by marrow macrophages: a potential mechanism for human immunodeficiency virus-1-induced hematopoietic suppression.Blood80(12) , 3036–3043 (1992).
  • Zhang M , LiX, PangXet al.: Identification of a potential HIV-induced source of bystander-mediated apoptosis in T cells: upregulation of trail in primary human macrophages by HIV-1 tat.J. Biomed. Sci.8(3) , 290–296 (2001).
  • Zagury D , LachgarA, ChamsVet al.: Interferon α and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS.Proc. Natl Acad. Sci. USA95(7) , 3851–3856 (1998).
  • Viscidi RP , MayurK, LedermanHM, FrankelAD: Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1.Science246(4937) , 1606–1608 (1989).
  • Gougeon ML : Apoptosis as an HIV strategy to escape immune attack.Nat. Rev. Immunol.3(5) , 392–404 (2003).
  • Westendorp MO , FrankR, OchsenbauerCet al.: Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120.Nature375(6531) , 497–500 (1995).
  • Orenstein JM : Ultrastructural markers of AIDS.Lancet322(8344) , 284–285 (1983).
  • Francis ML , MeltzerMS, GendelmanHE: Interferons in the persistence, pathogenesis, and treatment of HIV infection.AIDS Res. Hum. Retroviruses8(2) , 199–207 (1992).
  • Orenstein JM , PrebleOT, KindP, SchulofR: The relationship of serum α-interferon and ultrastructural markers in HIV-seropositive individuals.Ultrastruct. Pathol.11(5–6) , 673–679 (1987).
  • Badou A , BennasserY, MoreauMet al.: Tat protein of human immunodeficiency virus type 1 induces interleukin-10 in human peripheral blood monocytes: implication of protein kinase C-dependent pathway.J. Virol.74(22) , 10551–10562 (2000).
  • Kekow J , WachsmanW, McCutchanJAet al.: Transforming growth factor β and noncytopathic mechanisms of immunodeficiency in human immunodeficiency virus infection.Proc. Natl Acad. Sci. USA87(21) , 8321–8325 (1990).
  • Whiteside TL : The tumor microenvironment and its role in promoting tumor growth.Oncogene27(45) , 5904–5912 (2008).
  • Folkman J : The role of angiogenesis in tumor growth.Semin. Cancer Biol.3(2) , 65–71 (1992).
  • Folkman J : Tumor angiogenesis: therapeutic implications.N. Engl. J. Med.285(21) , 1182–1186 (1971).
  • Pouyssegur J , DayanF, MazureNM: Hypoxia signalling in cancer and approaches to enforce tumour regression.Nature441(7092) , 437–443 (2006).
  • Hirakawa S , KodamaS, KunstfeldRet al.: VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis.J. Exp. Med.201(7) , 1089–1099 (2005).
  • Hussong JW , RodgersGM, ShamiPJ: Evidence of increased angiogenesis in patients with acute myeloid leukemia.Blood95(1) , 309–313 (2000).
  • Santin AD , HermonatPL, HiserodtJCet al.: Differential transforming growth factor-β secretion in adenocarcinoma and squamous cell carcinoma of the uterine cervix.Gynecol. Oncol.64(3) , 477–480 (1997).
  • Gastl GA , AbramsJS, NanusDMet al.: Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression.Int. J. Cancer55(1) , 96–101 (1993).
  • Angelo LS , TalpazM, KurzrockR: Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53.Cancer Res.62(3) , 932–940 (2002).
  • Smith PC , HobischA, LinDL, CuligZ, KellerET: Interleukin-6 and prostate cancer progression.Cytokine Growth Factor Rev.12(1) , 33–40 (2001).
  • Vicari AP , CauxC, TrinchieriG: Tumour escape from immune surveillance through dendritic cell inactivation.Semin. Cancer Biol.12(1) , 33–42 (2002).
  • Noel A , JostM, LambertV, LecomteJ, RakicJM: Anti-angiogenic therapy of exudative age-related macular degeneration: current progress and emerging concepts.Trends Mol. Med.13(8) , 345–352 (2007).
  • Escudier B , CosaertJ, PisaP: Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma.Expert Rev. Anticancer Ther.8(10) , 1545–1557 (2008).
  • Ciulla TA , RosenfeldPJ: Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.Curr. Opin. Ophthalmol.20(3) , 158–165 (2009).
  • Ishizaka K , IshizakaT: Human reaginic antibodies and immunoglobulin E.J. Allergy42(6) , 330–363 (1968).
  • Zurawski G , de Vries JE: Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol. Today15(1) , 19–26 (1994).
  • Ricci M : IL-4: a key cytokine in atopy.Clin. Exp. Allergy24(9) , 801–812 (1994).
  • Kuhn R , RajewskyK, MullerW: Generation and analysis of interleukin-4 deficient mice.Science254(5032) , 707–710 (1991).
  • de Vries JE : The role of IL-13 and its receptor in allergy and inflammatory responses.J. Allergy Clin. Immunol.102(2) , 165–169 (1998).
  • Shirakawa I , DeichmannKA, IzuharaIet al.: Atopy and asthma: genetic variants of IL-4 and IL-13 signalling.Immunol. Today21(2) , 60–64 (2000).
  • Sadick MD , HeinzelFP, HoladayBJet al.: Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon γ-independent mechanism.J. Exp. Med.171(1) , 115–127 (1990).
  • Beck JT , HsuSM, WijdenesJet al.: Brief report: alleviation of systemic manifestations of Castleman‘s disease by monoclonal anti-interleukin-6 antibody.N. Engl. J. Med.330(9) , 602–605 (1994).
  • Bendtzen K , AinsworthM, SteenholdtC, ThomsenOO, BrynskovJ: Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-α antibodies.Scand. J. Gastroenterol.44(7) , 774–781 (2009).
  • Ramon G : Sur le pouvoir floculant et sur les propriétés immunisantes d‘une toxine diphtérique rendue anatoxique (anatoxine).C. R. Acad. Sci.178 , 1338–1340 (1923).
  • Relyveld EH , Ben-EfraimS: Preparation of vaccines by the action of glutaraldehyde on toxins, bacteria, viruses, allergens, and cells.Methods Enzymol.93 , 24–60 (1983).
  • Bizzini B , AchourA: ‘Kinoids‘: the basis for anticytokine immunization and their use in HIV infection.Cell. Mol. Biol. (Noisy-le-grand)41(3) , 351–356 (1995).
  • Harris JR , MarklJ: Keyhole limpet hemocyanin (KLH): a biomedical review.Micron30(6) , 597–623 (1999).
  • Bizzini B : Proceedings of an Informal Consultation on the World Health Organization Requirements for Diphtheria, Tetanus, Pertussis and Combined Vaccines. Manclark CR (Ed.). Department of Health and Human Services, US Public Health Service, MD, USA, 252 (1991).
  • Gringeri A , MusiccoM, HermansPet al.: Active anti-interferon-α immunization: a European–Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1-infected patients (the EURIS study).J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.20(4) , 358–370 (1999).
  • Le Buanec H , DelavalleeL, BessisNet al.: TNF-α kinoid vaccination-induced neutralizing antibodies to TNF-α protect mice from autologous TNF-α-driven chronic and acute inflammation.Proc. Natl Acad. Sci. USA103(51) , 19442–19447 (2006).
  • Rad FH , Le Buanec H, Paturance S et al.: VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc. Natl Acad. Sci. USA104(8) , 2837–2842 (2007).
  • Zagury D , Le Buanec H, Mathian A et al.: IFN-α kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proc. Natl Acad. Sci. USA106(13) , 5294–5299 (2009).
  • Waterston AM , GumbrellL, BrattTet al.: Phase I study of TNF-α AutoVaccine in patients with metastatic cancer.Cancer Immunol. Immunother.54(9) , 848–857 (2005).
  • Le Buanec H , PaturanceS, CouillinIet al.: Control of allergic reactions in mice by an active anti-murine IL-4 immunization.Vaccine25(41) , 7206–7016 (2007).
  • Guy B : The perfect mix: recent progress in adjuvant research.Nat. Rev. Microbiol.5(7) , 505–517 (2007).
  • Aucouturier J , AscarateilS, DupuisL: The use of oil adjuvants in therapeutic vaccines.Vaccine24(Suppl. 2) , 44–45 (2006).
  • Bard F , CannonC, BarbourRet al.: Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease.Nat. Med.6(8) , 916–919 (2000).
  • Holmes C , BocheD, WilkinsonDet al.: Long-term effects of Aβ42 immunisation in Alzheimer‘s disease: follow-up of a randomised, placebo-controlled Phase I trial.Lancet372(9634) , 216–223 (2008).
  • Gringeri A , Le Buanec H, Muça-Perja M et al.: Reduced drug-induced lipodystrophy and HCV liver disease progression in anti-interferon α (IFN-α) and anti-Tat vaccinees. Presented at: International Meeting of the Institute of Human Virology. Baltimore, MD, USA, 29 September–3 October 2003.
  • Lau JY , SheronN, MorrisAGet al.: Interferon-α receptor expression and regulation in chronic hepatitis B virus infection.Hepatology13(2) , 332–338 (1991).
  • Pasparakis M , AlexopoulouL, EpiskopouV, KolliasG: Immune and inflammatory responses in TNF α-deficient mice: a critical requirement for TNF α in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response.J. Exp. Med.184(4) , 1397–1411 (1996).
  • Cytokine Knockouts (2nd edition). Fantuzzi G: (Ed.). Humana Press, NY, USA (2003)
  • Olleros ML , GulerR, VesinDet al.: Contribution of transmembrane tumor necrosis factor to host defense against Mycobacterium bovis bacillus Calmette–Guerin and Mycobacterium tuberculosis infections.Am. J. Pathol.166(4) , 1109–1120 (2005).
  • Mathian A , AmouraZ, AdamEet al.: Active immunization with IFNα kinoid induces polyclonal antibodies that neutralize IFNα from systemic lupus erythematosus. Presented at: 2009 ACR/ARHP Annual Scientific Meeting. Philadelphia, PA, USA, 16–21 October 2009.
  • Bachmann MF , DyerMR: Therapeutic vaccination for chronic diseases: a new class of drugs in sight.Nat. Rev. Drug Discov.3(1) , 81–88 (2004).
  • Spohn G , GulerR, JohansenPet al.: A virus-like particle-based vaccine selectively targeting soluble TNF-α protects from arthritis without inducing reactivation of latent tuberculosis.J. Immunol.178(11) , 7450–7457 (2007).
  • Spohn G , KellerI, BeckMet al.: Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis.Eur. J. Immunol.38(3) , 877–887 (2008).
  • Ma Y , MaAG, PengZ: A potential immunotherapy approach: mucosal immunization with an IL-13 peptide-based virus-like particle vaccine in a mouse asthma model.Vaccine25(47) , 8091–8099 (2007).
  • Rohn TA , JenningsGT, HernandezMet al.: Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis.Eur. J. Immunol.36(11) , 2857–2867 (2006).
  • Gonzalez G , CrombetT, CatalaMet al.: A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial.Ann. Oncol.9(4) , 431–435 (1998).
  • Richard M , GrencisRK, HumphreysNE, RenauldJC, Van Snick J: Anti-IL-9 vaccination prevents worm expulsion and blood eosinophilia in Trichuris muris-infected mice. Proc. Natl Acad. Sci. USA97(2) , 767–772 (2000).
  • Uyttenhove C , ArendseB, StroobantV, BrombacherF, Van Snick J: Development of an anti-IL-12 p40 auto-vaccine: protection in experimental autoimmune encephalomyelitis at the expense of increased sensitivity to infection. Eur. J. Immunol.34(12) , 3572–3581 (2004).
  • Uyttenhove C , Van Snick J: Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis. Eur. J. Immunol.36(11) , 2868–2874 (2006).
  • Svenson M , HansenMB, ThomsenARet al.: Cytokine vaccination: neutralising IL-1α autoantibodies induced by immunisation with homologous IL-1α.J. Immunol. Methods236(1–2) , 1–8 (2000).
  • Tan GH , SuJM, WangCCet al.: A recombinant DNA plasmid encoding the human interleukin-5 breaks immunological tolerance and inhibits airway inflammation in a murine model of asthma.Int. Arch. Allergy Immunol.145(4) , 313–323 (2008).
  • Dalum I , JensenMR, HinderssonP, ElsnerHI, MouritsenS: Breaking of B cell tolerance toward a highly conserved self protein.J. Immunol.157(11) , 4796–4804 (1996).
  • Galle P , HougsL, BaringtonTet al.: Knocking out IL-6 by vaccination.Eur. J. Immunol.34(1) , 291–300 (2004).
  • Bertin-Maghit SM , CapiniCJ, BessisNet al.: Improvement of collagen-induced arthritis by active immunization against murine IL-1β peptides designed by molecular modelling.Vaccine23(33) , 4228–4235 (2005).
  • Zuany-Amorim C , ManliusC, DalumIet al.: Induction of TNF-α autoantibody production by AutoVac TNF106: a novel therapeutic approach for the treatment of allergic diseases.Int. Arch. Allergy Immunol.133(2) , 154–163 (2004).
  • Grunewald J , HuntGS, DongLet al.: Mechanistic studies of the immunochemical termination of self-tolerance with unnatural amino acids.Proc. Natl Acad. Sci. USA106(11) , 4337–4342 (2009).
  • Shealy DJ , WooleyPH, EmmellEet al.: Anti-TNF-α antibody allows healing of joint damage in polyarthritic transgenic mice.Arthritis Res.4(5) , R7 (2002).
  • Delavallee L , Le Buanec H, Bessis N et al.: Early and long-lasting protection from arthritis in tumour necrosis factor α (TNFα) transgenic mice vaccinated against TNFα. Ann. Rheum. Dis.67(9) , 1332–1338 (2008).
  • Delavallee L , SemeranoL, AssierEet al.: Active immunization to tumor necrosis factor-α is effective in treating chronic established inflammatory disease: a long-term study in a transgenic model of arthritis.Arthritis Res. Ther.11(6) , R195 (2009).
  • Tobe T , OrtegaS, LunaJDet al.: Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model.Am. J. Pathol.153(5) , 1641–1646 (1998).
  • Bigot K , ProvostA, Grouard-VogelGet al.: Encouraging results of a VEGF kinoid against experimental choroidal neovascularization. Presented at: European Association for Vision and Eye Research (EVER) International Meeting 2009. Portoroz, Slovenia, 30 September–3 October 2009.
  • Schnyder-Candrian S , TogbeD, CouillinIet al.: Interleukin-17 is a negative regulator of established allergic asthma.J. Exp. Med.203(12) , 2715–2725 (2006).
  • Benji P , BurgerF, KrugerDet al.: Therapeutic immunization against TNF with a TNF-kinoid in Crohn‘s disease patients is safe and induces anti-TNF antibodies. Presented at: GASTRO2009 International Meeting UEGW/WCOG. London, UK, 20–25 November 2009.
  • Gringeri A , SantagostinoE, MannucciPMet al.: A randomized, placebo-controlled, blind anti-AIDS clinical trial: safety and immunogenicity of a specific anti-IFN a immunization.J. Acquir. Immune Defic. Syndr.7(9) , 978–988 (1994).
  • Gringeri A , SantagostinoE, Muca-PerjaMet al.: Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients.J. Hum. Virol.1(4) , 293–298 (1998).
  • Ratsimandresy RA , RappaportJ, ZaguryJF: Anti-cytokine therapeutics: history and update.Curr. Pharm. Des.15(17) , 1998–2025 (2009).
  • Aringer M , SmolenJS: Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus.Expert Opin. Drug Saf.7(4) , 411–419 (2008).
  • Pache I , RoglerG, FelleyC: TNF-α blockers in inflammatory bowel diseases: practical consensus recommendations and a user‘s guide.Swiss Med. Wkly139(19–20) , 278–287 (2009).
  • Tubach F , SalmonD, RavaudPet al.: Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry.Arthritis Rheum.60(7) , 1884–1894 (2009).
  • Wolfe F , MichaudK: The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.Arthritis Rheum.56(5) , 1433–1439 (2007).
  • Mariette X , TubachF, BagheriHet al.: Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry.Ann. Rheum. Dis.69(2) , 400–408 (2010).
  • Hoentjen F , van Bodegraven AA: Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J. Gastroenterol.15(17) , 2067–2073 (2009).
  • Peyrin-Biroulet L , DesreumauxP, SandbornWJ, ColombelJF: Crohn‘s disease: beyond antagonists of tumour necrosis factor.Lancet372(9632) , 67–81 (2008).
  • Rutgeerts P , Van Assche G, Vermeire S: Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology126(6) , 1593–1610 (2004).
  • Hanauer SB , FeaganBG, LichtensteinGRet al.: Maintenance infliximab for Crohn‘s disease: the ACCENT I randomised trial.Lancet359(9317) , 1541–1549 (2002).
  • Sandborn WJ , FeaganBG, StoinovSet al.: Certolizumab pegol for the treatment of Crohn‘s disease.N. Engl. J. Med.357(3) , 228–238 (2007).
  • Rubbert-Roth A , FinckhA: Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review.Arthritis Res. Ther.11(Suppl. 1) , S1 (2009).
  • Afif W , LoftusEV Jr, Faubion WA et al.: Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am. J. Gastroenterol. DOI: 10.1038/ajg.2010.9 (2010) (Epub ahead of print).
  • Albert D , DunhamJ, KhanSet al.: Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.Ann. Rheum. Dis.67(12) , 1724–1731 (2008).
  • Britschgi M , OlinCE, JohnsHTet al.: Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer‘s disease.Proc. Natl Acad. Sci. USA106(29) , 12145–12150 (2009).
  • de Lemos Rieper C , GalleP, HansenMB: Characterization and potential clinical applications of autoantibodies against cytokines.Cytokine Growth Factor Rev.20(1) , 61–75 (2009).
  • Watanabe M , UchidaK, NakagakiKet al.: Anti-cytokine autoantibodies are ubiquitous in healthy individuals.FEBS Lett.581(10) , 2017–2021 (2007).
  • Giusti RM , CohenMH, KeeganP, PazdurR: FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer.Oncologist14(3) , 284–290 (2009).
  • Reynolds NA , WagstaffAJ: Cetuximab: in the treatment of metastatic colorectal cancer.Drugs64(1) , 109–118; discussion, 119–121 (2004).
  • Vogel CL , CobleighMA, TripathyDet al.: First-line Herceptin monotherapy in metastatic breast cancer.Oncology61(Suppl. 2) , 37–42 (2001).
  • Disis ML , WallaceDR, GooleyTAet al.: Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer.J. Clin. Oncol.27(28) , 4685–4692 (2009).
  • Sobrero A , AcklandS, ClarkeSet al.: Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.Oncology77(2) , 113–119 (2009).
  • Heier JS , AntoszykAN, PavanPRet al.: Ranibizumab for treatment of neovascular age-related macular degeneration: a Phase I/II multicenter, controlled, multidose study.Ophthalmology113(4) , 633 E1–E4 (2006).
  • Lachmann HJ , Kone-PautI, Kuemmerle-DeschnerJBet al.: Use of canakinumab in the cryopyrin-associated periodic syndrome.N. Engl. J. Med.360(23) , 2416–2425 (2009).
  • Le Loet X , NordstromD, RodriguezMet al.: Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial.J. Rheumatol.35(8) , 1538–1544 (2008).
  • Lin M , MingA, ZhaoM: Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study.Clin. Transplant.20(3) , 325–329 (2006).
  • Hart TK , BlackburnMN, Brigham-BurkeMet al.: Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma.Clin. Exp. Immunol.130(1) , 93–100 (2002).
  • Flood-Page P , Menzies-GowA, PhippsSet al.: Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics.J. Clin. Invest.112(7) , 1029–1036 (2003).
  • Hertz M , MahalingamS, DalumIet al.: Active vaccination against IL-5 bypasses immunological tolerance and ameliorates experimental asthma.J. Immunol.167(7) , 3792–3799 (2001).
  • Tan GH , WangCC, HuangFYet al.: Active immunotherapy of allergic asthma with a recombinant human interleukin-5 protein as vaccine in a murine model.Chin. Med. J.120(17) , 1517–1522 (2007).
  • White B , LeonF, WhiteW, RobbieG: Two first-in-human, open-label, Phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers.Clin. Ther.31(4) , 728–740 (2009).
  • Lima XT , AbuabaraK, KimballAB, LimaHC: Briakinumab.Expert Opin. Biol. Ther.9(8) , 1107–1113 (2009).
  • Bree A , SchlermanFJ, WadanoliMet al.: IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys.J. Allergy Clin. Immunol.119(5) , 1251–1257 (2007).
  • Yao Y , RichmanL, HiggsBWet al.: Neutralization of interferon-α/β-inducible genes and downstream effect in a Phase I trial of an anti-interferon-α monoclonal antibody in systemic lupus erythematosus.Arthritis Rheum.60(6) , 1785–1796 (2009).
  • Reinisch W , de Villiers W, Bene L et al.: Fontolizumab in moderate to severe Crohn‘s disease: a Phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm. Bowel Dis.16(2) , 233–242 (2010).
  • Tracey D , KlareskogL, SassoEH, SalfeldJG, TakPP: Tumor necrosis factor antagonist mechanisms of action: a comprehensive review.Pharmacol. Ther.117(2) , 244–279 (2008).
  • Jennings GT , BachmannMF: Immunodrugs: therapeutic VLP-based vaccines for chronic diseases.Annu. Rev. Pharmacol. Toxicol.49 , 303–326 (2009).
  • Spohn G , SchwarzK, MaurerPet al.: Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles.J. Immunol.175(9) , 6211–6218 (2005).
  • Wallace DJ , StohlW, FurieRAet al.: A Phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.Arthritis Rheum.61(9) , 1168–1178 (2009).
  • Youssef S , WildbaumG, KarinN: Prevention of experimental autoimmune encephalomyelitis by MIP-1α and MCP-1 naked DNA vaccines.J. Autoimmun.13(1) , 21–29 (1999).
  • Haringman JJ , GerlagDM, SmeetsTJet al.: A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis.Arthritis Rheum.54(8) , 2387–2392 (2006).
  • Ding C , LiJ, ZhangX: Bertilimumab Cambridge Antibody Technology Group.Curr. Opin. Investig. Drugs5(11) , 1213–1218 (2004).
  • Melnikova VO , Bar-EliM: Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8.Pigment Cell Res.19(5) , 395–405 (2006).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.